EP4257126A3 - Polymeric bile acid nanocompositions targeting the pancreas and colon - Google Patents

Polymeric bile acid nanocompositions targeting the pancreas and colon Download PDF

Info

Publication number
EP4257126A3
EP4257126A3 EP23178282.2A EP23178282A EP4257126A3 EP 4257126 A3 EP4257126 A3 EP 4257126A3 EP 23178282 A EP23178282 A EP 23178282A EP 4257126 A3 EP4257126 A3 EP 4257126A3
Authority
EP
European Patent Office
Prior art keywords
pancreas
colon
insulin
nanocompositions
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23178282.2A
Other languages
German (de)
French (fr)
Other versions
EP4257126A2 (en
Inventor
Tarek M Fahmy
Jung Seok Lee
Dongin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP4257126A2 publication Critical patent/EP4257126A2/en
Publication of EP4257126A3 publication Critical patent/EP4257126A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical composition containing poly(bile) acid (PBA) polymers for oral delivery of agent(s) show enhanced uptake by the pancreas, liver, and colon. These nanoparticles show significant retention in the pancreas and colon and are therefore useful for selective delivery. The examples demonstrate efficacy of oral administration of insulin to treat diabetes, and oral induction of tolerance by administration of insulin or ovalbumin in combination with rapamycin. Diabetic animals treated with the insulin or insulin with rapamycin showed normalization of blood glucose levels.
EP23178282.2A 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon Pending EP4257126A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214648P 2015-09-04 2015-09-04
EP16766761.7A EP3347794B1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon
PCT/US2016/050291 WO2017041053A1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP16766761.7A Division EP3347794B1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon
EP16766761.7A Division-Into EP3347794B1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon

Publications (2)

Publication Number Publication Date
EP4257126A2 EP4257126A2 (en) 2023-10-11
EP4257126A3 true EP4257126A3 (en) 2023-12-06

Family

ID=56940414

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23178282.2A Pending EP4257126A3 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon
EP16766761.7A Active EP3347794B1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16766761.7A Active EP3347794B1 (en) 2015-09-04 2016-09-02 Polymeric bile acid nanocompositions targeting the pancreas and colon

Country Status (10)

Country Link
US (1) US10864170B2 (en)
EP (2) EP4257126A3 (en)
CN (1) CN108351687B (en)
AU (3) AU2016316119A1 (en)
CA (1) CA2997442C (en)
ES (1) ES2957882T3 (en)
IL (1) IL257649B (en)
PH (1) PH12018500449A1 (en)
PL (1) PL3347794T3 (en)
WO (1) WO2017041053A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (en) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） Sugar-targeted therapeutic agent
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US20210220481A1 (en) * 2018-08-03 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Biocompatible tolerogenic nanoparticles
CN113398267B (en) * 2020-03-17 2023-05-05 中国医学科学院药物研究所 Application of EphB4 as target in screening of insulin sensitivity increasing drugs or models
WO2021258042A1 (en) * 2020-06-19 2021-12-23 Yale University Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869106A (en) * 2006-06-23 2006-11-29 武汉大学 Method of preparing polymer nanometerl micron ball assisted by ultrasonic wave
WO2009038591A1 (en) * 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
CN102351967B (en) * 2011-07-07 2014-01-29 清华大学 High-molecular material containing cholic acid and liver-targeting drug delivery nanoparticle modified by same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR651814A (en) 1927-03-28 1929-02-28 Demag Ag Variable boom crane, with horizontal displacement of the boom pulley and the load
FR900523A (en) 1942-11-11 1945-07-02 Process for preparing protein extracts of animal origin
FR900520A (en) 1943-12-13 1945-07-02 New gauge system
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (en) 1980-04-09 1986-12-03 Eurand Spa PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
WO1993019763A1 (en) 1992-03-30 1993-10-14 American Home Products Corporation Rapamycin formulation for iv injection
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
CN1046944C (en) 1993-12-17 1999-12-01 山道士有限公司 Rapamycin derivatives useful as immunosuppressants
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
FR2721510B1 (en) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticles filterable under sterile conditions.
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6149663A (en) 1999-08-17 2000-11-21 Scimed Life Systems, Inc. Guide wire brake for ablation assembly
WO2002089820A1 (en) 2001-05-09 2002-11-14 Mediplex Corporation Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
PL1608400T3 (en) 2003-03-28 2010-11-30 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
DE602005021756D1 (en) 2004-02-13 2010-07-22 Nod Pharmaceuticals Inc PARTICLES WITH CORE OF CALCIUM PHOSPHATE NANOPARTICLES, BIOMOLECOL AND GALLENIC ACID, METHOD OF MANUFACTURE AND THERAPEUTIC USE
EP1816441B1 (en) * 2004-10-04 2018-09-12 Hamamatsu Photonics K.K. Encoder
KR100762954B1 (en) * 2006-01-26 2007-10-04 나재운 Anti-cancer Agent Loaded Hydrophobic Bile Acid Conjugated Hydrophilic Chitosan Oligosaccharide Nanoparticles and Preparation Method Thereof
US20100178299A1 (en) 2007-02-13 2010-07-15 Northeastern University Methods and compositions for improving immune responses
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9956291B2 (en) 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
AU2015339005B2 (en) 2014-10-31 2020-12-17 Hee Sook Hwang Compositions and methods for bile acid particles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869106A (en) * 2006-06-23 2006-11-29 武汉大学 Method of preparing polymer nanometerl micron ball assisted by ultrasonic wave
WO2009038591A1 (en) * 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
CN102351967B (en) * 2011-07-07 2014-01-29 清华大学 High-molecular material containing cholic acid and liver-targeting drug delivery nanoparticle modified by same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAMGE C ET AL: "POLY(ALKYL CYANOACRYLATE) NANOSPHERES FOR ORAL ADMINISTRATION OF INSULIN", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 86, no. 12, 1 December 1997 (1997-12-01), pages 1403 - 1409, XP000723752, ISSN: 0022-3549, DOI: 10.1021/JS970124I *
STANCIU MAGDALENA C ET AL: "New biocompatible amphiphilic diblock copolymer based on dextran", EUROPEAN POLYMER JOURNAL, PERGAMON PRESS LTD OXFORD, GB, vol. 71, 13 August 2015 (2015-08-13), pages 352 - 363, XP029276551, ISSN: 0014-3057, DOI: 10.1016/J.EURPOLYMJ.2015.08.011 *

Also Published As

Publication number Publication date
AU2020267191A1 (en) 2020-12-03
PL3347794T3 (en) 2024-01-03
AU2020267191B2 (en) 2022-08-18
CA2997442A1 (en) 2017-03-09
IL257649A (en) 2018-04-30
EP3347794A1 (en) 2018-07-18
EP3347794C0 (en) 2023-07-19
US20180243226A1 (en) 2018-08-30
AU2016316119A1 (en) 2018-04-19
EP3347794B1 (en) 2023-07-19
AU2020200008A1 (en) 2020-01-30
CN108351687A (en) 2018-07-31
CN108351687B (en) 2022-01-07
PH12018500449A1 (en) 2018-09-17
EP4257126A2 (en) 2023-10-11
IL257649B (en) 2021-12-01
CA2997442C (en) 2021-01-26
ES2957882T3 (en) 2024-01-29
US10864170B2 (en) 2020-12-15
AU2020200008B2 (en) 2020-09-10
WO2017041053A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
EP4257126A3 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
MY158890A (en) Pegylated insulin lispro compounds
MX2015011393A (en) Modified poly(beta-amino ester)s for drug delivery.
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
PH12017501910A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
EP3000497A3 (en) Cannula insertion detection
RS52880B (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
WO2013123492A3 (en) Glucose-responsive microgels for closed loop insulin delivery
EP3147285A3 (en) Purinone compounds as kinase inhibitors
WO2012166923A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
WO2009148777A3 (en) Implantable drug delivery devices having alternating hydrophilic and amphiphilic polymer layers
MX366314B (en) Treating diabetes melitus using insulin injections administered with varying injection intervals.
WO2013184646A3 (en) Dosing regimens for subcutaneously infusible acidic compositions
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
EP2422816A4 (en) A drug composition for treating tumor with polymeric micelle encapsulating antineoplastic
MX365688B (en) Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin.
WO2015106295A3 (en) Enolase 1 (eno1) compositions and uses thereof
MX367070B (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine.
GB2524924A (en) Vitamin functionalized gel-forming block copolymers for biomedical applications
WO2014075203A8 (en) Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline
WO2011072627A3 (en) Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs especially for treatment of solid tumours
GB2551453A (en) Nanocarrier delivery system for hydrophobic substances
SG195192A1 (en) Non-peptidyl polymer-insulin multimer and method for producing the same
EA200801388A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS AND DISEASES MEDIATED BY HELICOBACTER PILORY BASED ON POLYMERIC NANOPARTICLES, ITS TREATMENT METHOD AND TREATMENT METHOD
PE20070701A1 (en) THERAPY AGAINST CANCER WITH ESTROGEN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3347794

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20231102BHEP

Ipc: A61P 3/10 20060101ALI20231102BHEP

Ipc: A61P 1/18 20060101ALI20231102BHEP

Ipc: A61P 1/00 20060101ALI20231102BHEP

Ipc: A61K 45/00 20060101ALI20231102BHEP

Ipc: A61K 38/28 20060101ALI20231102BHEP

Ipc: A61K 31/436 20060101ALI20231102BHEP

Ipc: A61K 31/00 20060101ALI20231102BHEP

Ipc: A61K 9/00 20060101ALI20231102BHEP

Ipc: H04M 1/725 20210101ALI20231102BHEP

Ipc: G06F 3/01 20060101ALI20231102BHEP

Ipc: A61K 9/51 20060101AFI20231102BHEP